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ABSTRACT The deactivation of the bovine G-protein-coupled receptor, rhodopsin, is a two-step process consisting of the
phosphorylation of speciﬁc serine and threonine residues in the cytoplasmic tail of rhodopsin by rhodopsin kinase. Subsequent
binding of the regulatory protein arrestin follows this phosphorylation. Previous results ﬁnd that at least three phosphorylatable
sites on the rhodopsin tail (T340) and at least two of the S338, S334, or S343 sites are needed for complete arrestin-mediated
deactivation. Thus, to elucidate the details of the interaction between rhodopsin with arrestin, we have employed both
a computational and an in vitro experimental approach. In this work, we ﬁrst simulated the interaction of the carboxy tail of
rhodopsin with arrestin using a Monte Carlo simulated annealing method. Since at this time phosphorylation of speciﬁc serines
and threonines is not possible in our simulations, we substitute either aspartic or glutamic acid residues for the negatively
charged phosphorylated residues required for binding. A total of 17 simulations were performed and analysis of this shows
speciﬁc charge-charge interactions of the carboxy tail of rhodopsin with arrestin. We then conﬁrmed these computational results
with assays of comparable constructed rhodopsin mutations using our in vitro assay. This dual computational/experimental
approach indicates that sites S334, S338, and T340 in rhodopsin and K14 and K15 on arrestin are indeed important in the
interaction of rhodopsin with arrestin, with a possible weaker S343 (rhodopsin)/K15 (arrestin) interaction.
INTRODUCTION
The extracellular signaling of hormones, light, and odorants is
facilitated by a large family of G-protein-coupled receptors.
Speciﬁcally, for phototransduction in mammalian rod photo-
receptors, this process involves the visual pigment apopro-
tein, rod opsin, and the chromophore, 11-cis-retinal. Initiation
of the phototransduction cascade occurs by isomerization of
the chromophore from 11-cis to all-trans leading to activation
of the receptor (Molday, 1998; Jacobs, 1998; Sakmar et al.,
2002). Once the signaling cascade has been activated, the
receptor must then be quickly inactivated. Speciﬁcally for
the photopigment rhodopsin, deactivation is initiated by
a receptor-speciﬁc serine/threonine kinase, rhodopsin kinase
(GRK1), which phosphorylates residues on the cytoplasmic
tail and hence initiates partial deactivation. Complete de-
activation of the receptor does not occur until a second
regulatory protein, arrestin, binds. The interaction between
receptor and arrestin results in the fast quenching of the signal
transduction by decreasing the coupling of the receptor to the
G-protein, transducin (Alloway and Dolph, 1999; Wilden
et al., 1986; Lohse et al., 1990, 1992).
Phosphorhodopsin induces a large conformational change
in arrestin which shifts this protein from an inactive, low-
afﬁnity binding state to an active high-afﬁnity binding state,
where there is a ﬁvefold increase of the afﬁnity of arrestin for
phosphorhodopsin (Kuhn et al., 1986). Mutagenic studies
have elucidated three regions of arrestin that respond to
different states of rhodopsin (inactive, active, and phosphor-
ylated; Gurevich, 1998). It is the interaction between
phosphorylated rhodopsin residues and the arrestin protein
that is of interest to our studies.
The cytoplasmic tail of rhodopsin contains seven possible
phosphorylation sites. In vivo, the identity and number of
phosphate groups incorporated into the tail is still under
investigation. Several studies have found evidence that up to
three phosphates are incorporated into the cytoplasmic tail
of rhodopsin (Zhang et al., 1997; Kennedy et al., 2001a;
Ablonczy et al., 2002; McDowell et al., 2001), and site-
speciﬁc mutagenesis indicates that at least two rhodopsin
phosphorylation sites are required for full desensitization
(McDowell et al., 2001), whereas studies with transgenic
mice indicate at least three phosphorylated resides are
required (Mendez et al., 2000). Candidate phosphorylation
sites include serine 334, serine 338, threonine 340, and serine
343 (Brannock et al., 1999; McDowell et al., 2001). The
mechanism that these phosphorylated residues play in the
desensitization process is still under investigation; however,
it is believed that they will initially interact with arrestin via
a charge-charge mechanism (Vishnivetskiy et al., 2000).
Therefore, our study aims to determine speciﬁc site-site
interactions between the cytoplasmic tail of rhodopsin and
arrestin using both computational methods and in vitro
biochemical assays. For our approach, we draw on previous
studies that have examined the regions necessary for this
interaction. Speciﬁc crystallographic studies of bovine
arrestin have elucidated regions that may respond to the
phosphorylated residues on rhodopsin. The crystal structure
of the inactive conformation of arrestin suggest that it is
composed of two b-sheets oriented in such a way as to create
a hydrophobic core between them (Gray-Keller et al., 1997).
Within this hydrophobic core there exist at least two salt
Submitted August 8, 2003, and accepted for publication December 12, 2003.
Address reprint requests to Asst. Prof. Susan K. Gregurick, Chemistry and
Biochemistry, University of Maryland, Baltimore County, 1000 Hilltop
Circle, Baltimore, MD 21250. Tel.: 410-455-8698; E-mail: greguric@umbc.
edu.
 2004 by the Biophysical Society
0006-3495/04/04/2445/10 $2.00
Biophysical Journal Volume 86 April 2004 2445–2454 2445
bridges which act to stabilize the low-afﬁnity binding state
(Hirsch et al., 1999). During activation, the phosphorylated
residues are believed to penetrate into the hydrophobic core
and thereby disrupt these salt bridges which then induces the
conformational change in arrestin to achieve an active high-
afﬁnity binding state (Vishnivetskiy et al., 2000, 1999;
Gurevich, 1998; Palczewski et al., 2001).
The initial interaction between rhodopsin and arrestin,
however, is not well understood. Vishnivetskiy et al. (2000)
proposed that it might be a charge-charge interaction between
two key positively charged lysine residues (Lys14 and Lys15)
on arrestin, interacting with the negatively charged phos-
phorylated residues of rhodopsin. This charge-charge inter-
action is thought to guide the rhodopsin into the polar core of
the arrestin protein and thus allow for arrestin’s conforma-
tional change. At present, thismechanism is still hypothetical;
however, it is based on site-speciﬁc mutation studies of
arrestin (K14A and K15A) that resulted in a nearly eightfold
reduction of rhodopsin binding (Vishnivetskiy et al., 2000).
It is the aim of this study to investigate the desensitization
process in G-protein-coupled receptors, from both a compu-
tational and experimental prospective. In particular, we will
study the rod-speciﬁc visual pigment, rhodopsin, in complex
with visual arrestin as a model system for this process. We
should point out that any simulation of phosphorylated
rhodopsin must contend with the fact that a molecular force
ﬁeld to describe speciﬁc phosphorylated residues does not
exist at this time. To address this issue, we will perform key
mutation studies to model the negatively charged phosphor-
ylated residues as either aspartic or glutamic acid. Therefore,
our simulations are only directly comparable to the experi-
mental work of McDowell et al. (2001) and the current
experiments.We stress that although this computational work
is of peptide binding to arrestin, it is believed that the larger
rhodopsin-arrestin complex will interact in a similar fashion
as the peptide-arrestin complex (McDowell et al., 2001; Puig
et al., 1995). To the best of our knowledge, this investigations
represent the ﬁrst such simulation of the desensitization
process. Recently, Orry and co-workers have begun a study of
identifying ligand binding sites in G-protein-coupled recep-
tors using a novel docking approach (Cavasotto et al., 2003;
Orry and Wallace, 2000). Our approach is slightly different
in that we are looking at speciﬁc protein-protein interactions,
allowing for full conformational ﬂexibility of both proteins.
Therefore, our approach is not suitable for a full screening
of drug assays, but is meant to simulate possible binding
events in the desensitization process.
EXPERIMENTAL MATERIALS AND METHODS
Construction, expression, and reconstitution of
rhodopsin mutants
A synthetic bovine rhodopsin gene was cloned into a bacterial eukaryotic
expression vector (pMT3), which is a modiﬁed form of the pMT2 vector.
Mutations were introduced in the synthetic bovine rhodopsin gene using the
QuickChange site-directed mutagenesis protocol (Stratagene, La Jolla, CA)
and were veriﬁed by sequencing. Rhodopsin mutants were transiently
expressed in COS-7 mammalian cells through transfection using Lipo-
fectAMINE (Invitrogen, Carlsbad, CA) reagent. Cells were harvested 48 h
post-transfection and the cell membranes were isolated by sucrose density-
gradient centrifugation as described previously in Weiss et al. (1994).
Rhodopsin concentrations of membrane preparations were approximated by
Western blot using mAb 4D2, an antibody against the N-terminus of bovine
rhodopsin (antibody was a gift from R. Molday). Blots were quantitated
using ImageQuant (Molecular Dynamics, Sunnyvale, CA) software. The
concentration of rhodopsin in membrane preparations varied between 50 and
100 nM. The samples were stored at –808C until ready for use. The 50-mL
rhodopsin samples were reconstituted with 360 mM 11-cis retinal at 48C for
1 h on a rotating plate.
Puriﬁcation of arrestin from bovine retinas
Arrestin was puriﬁed from dark-adapted bovine retinas according to the
method described by Hargrave (1986) and the samples were stored at –808C.
Puriﬁcation of transducin from bovine rod
outer segments
Transducin was puriﬁed as described by Wessling-Resnick and Johnson
(1987), and the protein was stored in 50% glycerol at –208C.
Expression and puriﬁcation of rhodopsin kinase
Rhodopsin kinase was expressed in High-Five insect cells (Invitrogen). A
viral construct containing the rhodopsin kinase gene was a gift from K.
Palczewski. High-Five cells were grown as a suspension culture to a cell
density of 13 106 cells/mL. High-Five cells were infected with baculovirus
containing RK gene at a multiplicity of infection ¼ 5. The cells were
incubated at 278C for 72 h and were harvested by centrifugation (10003 g)
of 50 mL aliquots and subsequently stored at –808C until ready for
puriﬁcation. For RK puriﬁcation, a single aliquot was thawed in ice water for
30 min and resuspended into 3 mL of homogenization buffer (10 mM BTP,
0.04% Tween 20). The cells were homogenized with a Dounce homogenizer
and the homogenate was mixed with 10 mL volume of regenerated DE52
resin (Whatman, Maidstone, Kent, UK). The kinase was eluted from the
column with 100 mMNaCl in the homogenization buffer. Rhodopsin kinase
positive fractions were veriﬁed using a ﬁlter-binding assay as described
previously by Brannock et al. (1999).
GTPgS
35-binding ﬁlter-binding assays
The ability of arrestin to bind to rhodopsin was indirectly measured through
measurement of transducin activation by rhodopsin. A ﬁlter-binding assay
was employed for this purpose. 2.5–5 picomoles of rhodopsin were
reconstituted in the presence of 360 mM 11-cis retinal in a 50 mL volume for
1 h on a vertically rotating platform at 30 rpm. 12 mL of the reconstituted
membranes were incubated in a buffer containing 30 mM BTP (pH 7.5),
3 mM MgCl2, 0.4 mM ATP, 0.3 mM DTT, and 2–4 mL kinase or kinase
elution buffer (see Arrestin-Mediated Rhodopsin Deactivation Assays,
below) to generate a ﬁnal volume of 35 mL. The mixture was incubated at
308C for 15 min under bright light. After the 15-min incubation, 15 mL of
arrestin or arrestin buffer were added to generate 60% of the ﬁnal arrestin
concentration. The mixture was incubated for another 15 min at 308C under
bright light. The reaction was terminated by placing the tubes on ice for 2
min, at which time reaction volumes were increased to generate 100% of the
ﬁnal arrestin concentration of 5 mM, 2 mM transducin, 100 mM NaCl, 10
mM Tris-Cl (pH 7.5), 5 mM MgCl2, and 1 mM DTT to a ﬁnal volume of
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90 mL. The reactions were started by adding 10 mL of 30 mM GTPgS
35. 10
mL of the reaction mixture were added to nitrocellulose ﬁlters on a Millipore
vacuum manifold at 30-s intervals. The ﬁlters were washed with 15 mL of
reaction buffer. Then the ﬁlters were added to 5 mL of scintillation ﬂuid
(Amersham Biosciences, Piscataway, NJ) and allowed to shake vigorously
overnight. Reactions rates were expressed as picomoles of GTPgS
35 bound
per min. The linear regressions were calculated using SigmaPlot software.
Arrestin-mediated rhodopsin deactivation assays
Arrestin-mediated rhodopsin deactivation was indirectly measured by
measuring transducin activation. Deactivation was expressed as percentage
of inhibition of transducin activation. For experiments requiring phosphor-
ylation of rhodopsin, three reactions were run simultaneously and the rates
of transducin activation (v) were calculated for each. Reaction rates were as
follows: v1 ¼ (–) kinase, (–) arrestin; v2 ¼ (1) kinase, (–) arrestin; and v3 ¼
(1) kinase, (1) arrestin. Enough kinase was added to the reaction so v2 ¼
50% forWt (v1). The decrease in rate of transducin activation due to arrestin-
mediated deactivation was given as: % inhibition¼ [1 (v3/v2)]100. For the
experiments with rhodopsin mutants that had glutamic acid and aspartic acid
substitutions, only two reactions were run. Reaction rates are as follows:
v1 ¼ (–) kinase, (–) arrestin, and v2 ¼ (–) kinase, (1) arrestin. For these
reactions, the decrease in rate of transducin activation due to arrestin-
mediated deactivation is given as: % inhibition ¼ [1  (v2/v1)] 100, and is
reported as an arrestin effect.
COMPUTATIONAL METHODS
Development of the Monte Carlo simulated
annealing algorithm
In understanding the possible interactions between two proteins (in this case
rhodopsin and arrestin) one needs to ﬁnd low energy minima of the complex.
This is similar, in spirit, to reaching the global energy minimum in ligand-
protein docking simulations (Trosset and Scheraga, 1998; Ewing and Kuntz,
1997; Makino and Kuntz, 1997; Eisen et al., 1994). Recently Orry and
Wallace utilized a docking approach to test their molecular model of the
Endothelin G-protein-coupled receptor (Orry and Wallace, 2000; Cavasotto
et al., 2003). Although this approach is highly successful for rigid-body (and
semiﬂexible) ligands, it will not allow for gross conformational changes to
occur in neither protein nor ligand. However, in our case, the entire complex
must be allowed to change conformation during the docking procedure. This
requires an effective search of all conformational space available to the
complex, as a function of conformational changes in either, or both, docking
proteins. In other words, both proteins must be able to refold upon
interaction. Therefore, a rigid-body docking algorithm would not sufﬁce for
this particular study where there is a deﬁnite conformational change in the
complex. Thus to effectively search the conformational space available to
the rhodopsin-arrestin complex, and hence get a sense of the interactions
between the two proteins, a torsion space, all-atom, Monte Carlo simulated
annealing algorithm was developed. Our algorithm is based on the all-atom
Monte Carlo algorithm of Avbelj and Moult developed for the folding of
small peptide structures (independent folding units) of between 11 and 14
residues in length (Avbelj and Moult, 1995). Although we utilized the same
free energy function (DG) and Monte Carlo sampling techniques as Avbelj
and Moult, we have extended the original algorithm to include a Monte
Carlo simulated annealing optimization procedure that will effectively
handle the refolding of protein-protein complexes.
In accordance with the original Monte Carlo algorithm, all of the atoms
were allowed to move in the simulation; however, only the bonding angles
(f, c, and x) were allowed to vary. Thus, the length of all bonds was kept
ﬁxed throughout the simulation. As in many standard Monte Carlo
techniques, an angle (backbone or side-chain) was selected and moved
and then a Metropolis criterion (Metropolis et al., 1953) was used to evaluate
the acceptance of the move as follows: if the free energy (DG) decreased, the






where Rnd is a random number, DG is the free energy of the complex,
k is the Boltzmann constant, and T is the current simulation temperature
(in K).
Angles were randomly chosen for a given move and the following move
set of Avbelj and Moult was employed throughout the simulations:
40% of the angles chosen were backbone angles.
60% of the angles chosen were side-chain angles.
Of the angles chosen (backbone or side-chain) the following types of
moves were allowed:
20% of all moves of angles were random.
60% of all moves of angles were taken from a precompiled library
(Holm and Sander, 1994).
20% of all moves of angles were local steps of 58.
If any given move resulted in a steric clash, then that move was immediately
disregarded and a new angle was chosen. The initial temperature of the
simulation was set at 300 K, the ﬁnal temperature was set to 50 K and
a cooling rate of 0.988 was employed. Thus the temperature decreased;0.1
K per every 10 simulation steps.
The free energy function (DG)
The MC-SA procedure optimizes geometry by optimizing an all-atom
implicit solvent free energy function. The free energy function used in the
MC-SA algorithm, deﬁned as DG, was derived by Avbelj and Moult (1995).
It is a potential of mean force based on a set of 114 nonhomologous protein


















The ﬁrst term of the free energy function is deﬁned as the local backbone
electrostatic energy. The sum over k, is a sum over all residues in the peptide.
SR(k) is a scaling dependent factor for a residue of type R at position k in the
sequence. ELk is the Coulomb energy of residue k, arising from interactions
between the NH and C¼0 groups with those of the ﬂanking residues (k1
and k11). In general, ELk is unfavorable for residues in a helical
conformation and favorable for extended conformations. The balance of
this term and that of main-chain hydrogen bonding will establish the
secondary structure of the protein.
The second term in the free energy function is deﬁned as the electrostatic
energy for the other intramolecular interactions. The sums over k and l are
over polar (k) and charged (l) residues of types i and j, for which the distance
between the proton donor and acceptor is shorter than 6.5 A˚. Ki(k)j(l) is
a scaling factor that is dependent on the type of charged or polar groups













where the sum overm and n are over all atoms of groups k and l. Here qm and
qn are the partial charges on the atoms, and rnm is the interatomic distance
between the two atoms.
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The third term in the free energy function (Eq. 1) is the solvation free
energy, and is based on the average local solvent accessibility of the atoms in
the observed conformation. For each set of atoms of the same type in any





ðAt  AmÞ: (3)
The exponent n is equal to 1 for carbon and sulfur atoms and 3 for oxygen
and nitrogen atoms. In Eq. 3, DAnl is the difference between the surface area
for an estimated random coil conformation (At; Lee and Richards, 1971) and
the exposed surface area for each atom, m, in the current conformation (Am).
Taken together, the three terms in Eq. 1 represent the potential of mean
force, which is optimized for the lowest energy conformation using the
Monte Carlo simulated annealing algorithm.
COMPUTATIONAL RESULTS
In an attempt to understand the role of the phosphorylated
residues in the desensitization process of G-protein-coupled
receptors, we have studied the interaction of various methyl-
capped rhodopsin cytoplasmic tail analogs (22 residues) with
the basal state of the rod-speciﬁc arrestin protein (R-arrestin)
(Protein Data Bank entry: 1CF1.pdb) (Hirsch et al., 1999).
Modeling the cytoplasmic tail of rhodopsin
Due to the size of rhodopsin (348-residue Protein Data Bank
entry: 1HZX.pdb), we are not yet able to include all of the
residues of the rhodopsin-arrestin complex in our simu-
lations. This is because the number of degrees of freedom, or
the number of movable dihedral angles, is too large for our
current simulation to handle. However, at present we are
only interested in studying the initial mechanism of the
desensitization process, which involves only the tail portion
of rhodopsin (residues 329–348) associating with the full
arrestin protein. Thus the remaining 328 residues of rho-
dopsin are relatively unimportant for this initial study. It
must be stressed, however, that the full 353 residues of arres-
tin are important for this study to ascertain if a confor-
mational change of this protein occurs when associating
with rhodopsin.
Because the cytoplasmic tail of rhodopsin is disordered in
solution and thus the x-ray crystal structure is not available
for these residues, we have modeled the tail as follows:
1. Methyl groups were added to both the N- and C-termini
of the cytoplasmic tail to avoid artiﬁcial end-end
interactions.
2. The 22-residue (methyl-capped) wild-type tail sequence
was ﬁrst modeled as an extended random coil.
3. This extended structure was then folded into a lowest free
energy conformation (global minimum) using the Monte
Carlo simulated annealing algorithm. We ﬁnd that the
lowest energy conformation of the wild-type (unphos-
phorylated) rhodopsin tail is DG ¼ –174.68 Kcal/mol,
and has a two-turn helix turn structure, as illustrated in
Fig. 1.
To ascertain that both the crystal structure of the basal
state of the arrestin and the cytoplasmic tail of rhodopsin are
in an energy minimum conﬁguration (before docking), we
also performed an energy minimization (MC-SA) on the
crystal structure of R-arrestin. We ﬁnd that the basal state of
arrestin protein has low energy of DG¼3464.86 kcal/mol,
with an RMS change of 0.539 A˚ as compared to the basal
state crystal structure. This indicates that the crystal structure
of arrestin is indeed at an energy minimum, hence any
conformational changes observed during association with
rhodopsin will be due to the interactions of the rhodopsin-
arrestin complex and not an artifact of our simulation
procedures.
The energy-minimized wild-type cytoplasmic tail of
rhodopsin was manually docked into the binding pocket of
arrestin using the program PSSHOW (Swanson, 1995). Care
was taken that the distance between most residues of
rhodopsin and arrestin were [9.0 A˚ apart, to begin our
simulations from an unbiased starting conﬁguration. Fig. 2
illustrates the wild-type complex, which is used as a starting
structure for the simulations.
Simulations and results of the
rhodopsin-arrestin complex
Monte Carlo simulated annealing, as described in Compu-
tational Methods, was performed on the wild-type complex
for 20,000 steps, beginning at 300 K and slowly reducing the
simulation temperature to 50 K during the course of the
simulation. We ﬁnd that neither the wild-type cytoplasmic
tail of rhodopsin nor arrestin changed conformation during
the simulation. This is seen in Table 1, where the Ca RMS
(root mean-square deviation) between the initial structure
(Fig. 2) and the ﬁnal structure (not shown) is 0.56 A˚. In fact,
the wild-type cytoplasmic tail began to leave the active site
during the simulation. Furthermore, there did not appear to
be any interaction between the two structures. This is seen in
Table 2, where the residue-residue distance (in A˚) is never
FIGURE 1 Lowest energy conﬁguration of the cytoplasmic tail of wild-
type rhodopsin, as found by the MC-SA method. The possible phosphor-
ylation sites (Ser/Thr) are illustrated in red.
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\8 A˚. This conﬁrms the experimental evidence that
unphosphorylated (wild-type) rhodopsin will not interact
with basal state arrestin. As a check of our simulation, we
mutated the seven serine/threonine residues to alanine in the
cytoplasmic tail of rhodopsin. We then performed the same
MC-SA simulation on this mutant complex and again
observed neither conformational changes (Table 1) nor
binding interactions in the complex (Table 2), as expected.
To ascertain if a possible charge-charge interaction occurs
between the cytoplasmic tail of rhodopsin and the basal state
of arrestin, we would ultimately need to phosphorylate the
serine/threonine residues in the cytoplasmic tail. However, at
this time such a simulation is not feasible. Thus we performed
two additional rhodopsin cytoplasmic tail mutation studies. In
one study, the serine/threonine residues were mutated to as-
partic acid, and in another study the serine/threonine residues
were mutated to glutamic acid. Although this may seem like
a drastic mutation, our simulations will be directly compared
to the aspartic and glutamic peptide tail analogous studies of
McDowell et al. (2001) as well as our current experimental
work. In the investigations of McDowell and co-workers, the
authors found evidence for an interaction between the all-
aspartic and all-glutamic peptide tail analogous with arrestin.
These interactions are not necessarily the same as in the
phosphorylated case but it is exactly this interaction which we
will elucidate as a foundation for future studies.
Simulations of the rhodopsin aspartic tail analog
In an attempt to elucidate the charge-charge interaction of
rhodopsin with R-arrestin we have performed computational
site-directed mutagenic studies of this system. Our muta-
tion studies include both aspartic acid and glutamic acid
mutations for the serine/threonine residues of the cytoplas-
mic tail of rhodopsin. We have also looked at different initial
orientations of the rhodopsin tail interacting and refolding
within the binding pocket of R-arrestin. We deﬁne one
orientation as parallel to the b-sheet of the Lys14/Lys15 pair
(Fig. 2), and the other initial orientation of the rhodopsin is
deﬁned as perpendicular (Fig. 3). Based on our Monte Carlo
simulated annealing simulations, we ﬁnd that only the
parallel orientation of the rhodopsin tail analog is capable of
interacting with the Lys14/Lys15 residues on arrestin. This
ﬁnding is best illustrated in Tables 1–3 and Fig. 4. In Table 1
we see that the CaRMS distance between the initial and ﬁnal
structures of the aspartic acid mutant complex is 1.9 A˚. The
change in this distance is due mostly to the refolding of the
aspartic mutant tail (CaRMS 5.3 A˚). In previous simulations
of both the wild-type and the alanine mutant, the tail did not
refold in the binding pocket of arrestin, indicating that the
charge-charge interaction is necessary for this refolding
process to occur.
Table 2 is a measure of the interaction distance between
key residues on rhodopsin and arrestin before (in) and after
(fn) the simulation. We ﬁnd that in a perpendicular ori-
entation this interaction distance is typically[12 A˚, indi-
cating no signiﬁcant interaction (simulation 3, Table 2).
However, when the initial orientation of the all-aspartic tail
mutant is parallel with the arrestin binding pocket, we ﬁnd
that after the simulation the interaction distance between
residues D334 (rhodopsin) and K15 (arrestin) is 3.7 A˚. We
believe this indicates a deﬁnite charge-charge interaction
(simulation 2, Table 2). We also ﬁnd three additional
interactions between residues D340 (rhodopsin) and K300
(6.48 A˚), H301 (3.51 A˚), and R29 (4.95 A˚) on the arrestin
protein. These additional interactions were not proposed in
the original model of Vishnivetskiy et al. (2000) and came as
a surprise to us. The ﬁnal structure of the all-aspartic acid tail
analog interacting with arrestin (simulation 2) is illustrated in
Fig. 4. The key residues are drawn in stick representation to
highlight these strong interactions.
We also determined if different parallel conformations
would interact in the same way with the R-arrestin protein.
To address this issue, we created a new initial parallel con-
formation by refolding the all-aspartic tail analog separately
into a new conﬁguration. We then placed this new structure
into the binding pocket of R-arrestin in a parallel conforma-
tion (Fig. 5). This new structure was also tested for all the
TABLE 1 Monte Carlo simulated annealing of C-tail rhodopsin/arrestin: energetics and RMS compared to starting structures
Simulation DG (Kcal/mol), tail DG (Kcal/mol), arrestin CaRMS tail CaRMS arrestin CaRMS complex
Wild-type 174.68 3591.63 0.694 0.157 0.566
ALA mutant 149.06 3507.95 0.461 0.090 0.290
GLU mutant 171.29 3501.23 5.58 0.56 1.67
ASP mutant 188.83 3523.45 5.269 0.133 1.902
DG ¼ free energy of the ﬁnal structure, relative to the unfolded state.
FIGURE 2 The initial structure of the cytoplasmic tail of rhodopsin
(parallel orientation) in association with R-arrestin.
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constitutive mutation studies we performed. We ﬁnd that
during the course of the simulation the rhodopsin resid-
ues D338 and D340 (parallel structure 2) interact with the
R-arrestin protein residues K14 and K15. However, this
interaction must be somewhat weaker as the interaction
distance is 6.2 A˚ and 8.7 A˚, respectively (simulation 4, Table
2). In a recent article by Kumar and Nussinov on the
relationship between ion pair geometry and electrostatic
strengths in proteins, the authors ﬁnd that if the ion pair is
within 4 A˚ this tends to be a stabilizing interaction, whereas
if the ion pair is[4 A˚ apart this tends to be a destabilizing
interaction (Kumar and Nussinov, 2002). This work is done
by exploring 11 nonhomologous protein NMR structures
and is based on a continuum electrostatic calculation.
Because we have not calculated the electrostatic strength
of our ion pairs separately, we cannot say if the short-range
3.7 A˚ distance is stabilizing or destabilizing to the complex.
We are now in the process of investigating this effect for the
ion pairs formed in the complex.
To ascertain if residues S334 and T340 are indeed important
interaction sites in rhodopsin we carried out a series of site-
directed computational mutations studies. We studied two
different mutant rhodopsin tail analogs, S334D:T340D and
S334D:S338D:T340D in all three starting conformations (Figs. 2,
3, and 5). We ﬁnd that both the double and triple mutant tail
analogs can interact with R-arrestin, although it is a somewhat
weaker interaction than with the full all-aspartic tail analog.
This is seen in Table 2, where the interaction distances are on
the order of 7–8 A˚ for the double and triple mutant analogs,
whereas it is 3.7 A˚ for the all-aspartic tail analog. Based on
these ﬁndings we made a prediction that the key residues for
interaction of the aspartic tail analog of rhodopsin with
arrestin were Ser334 and Thr340, with a secondary and
somewhat weaker interaction of Ser338 with arrestin.
Simulations of the rhodopsin glutamic tail analog
To address the issue of the effect of the side-chain size
(Brannock et al., 1999) on the charge-charge interaction, we
performed a glutamic acid mutation study. We begin with the
same initial parallel structure as in the all-aspartic mutation
study (Fig. 2). However, in this case, we mutated all-
rhodopsin tail serine and threonine residues to glutamic acid.
We then performed the same Monte Carlo simulated
annealing algorithm as before. The results are presented in
Tables 1–3. We see from Table 1 that the all-glutamic tail
TABLE 2 Monte Carlo simulated annealing of C-tail rhodopsin/arrestin: residue-residue interaction distances in A˚
Simulation Structure S334-K14 S338-K14 T340-K14 S334-K15 S338-K15 T340-K15
1. Wild-type in 13.6 12.6 14.6 13.4 6.9 9.6
1. Wild-type fn 15.9 9.7 11.9 14.5 8.0 9.7
2. All-D mutant* in 14.3 13.1 14.2 13.3 8.2 9.4
2. All-D mutant* fn 10.1 18.6 18.5 3.7 10.3 10.8
3. All-D mutanty in 23.8 25.5 24.4 16.1 15.9 12.3
3. All-D mutanty fn 24.4 24.6 24.4 16.2 14.9 12.8
4. All-D mutantz in 15.16 7.3 8.0 14.68 9.03 16.9
4. All-D mutantz fn 14.83 7.41 6.2 14.42 8.7 15.96
5. S334D:T340D* in 14.3 NA 14.2 13.3 NA 9.36
5. S334D:T340D* fn 17.3 NA 17.1 16.1 NA 14.9
6. S334D:T340Dy in 23.8 NA 24.4 16.1 NA 12.3
6. S334D:T340Dy fn 24.5 NA 24.3 16.7 NA 11.9
7. S334D:T340Dz in 20.3 NA 13.6 11.7 NA 9.1
7. S334D:T340Dz fn 21.6 NA 8.9 13.1 NA 7.6
8. S334D:S338D:T340D* in 14.3 13.1 14.2 13.3 8.2 9.6
8. S334D:S338D:T340D* fn 16.8 8.4 19.2 15.6 11.9 21.3
9. S334D:S338D:T340Dy in 25.1 23.6 16.9 15.2 13.2 5.2
9. S334D:S338D:T340Dy fn 25.4 23.9 16.6 15.2 13.2 4.9
10. S334D:S338D:T340Dz in 16.1 21.2 14.3 14.9 13.9 5.4
10. S334D:S338D:T340Dz fn 15.6 20.7 15.8 14.9 13.2 4.7
11. All-E mutant* in 16.96 11.95 13.44 19.92 6.18 8.05
11. All-E mutant* fn 17.70 6.65 16.18 18.40 13.22 22.26
12. S334E:T340E* in 14.24 NA 16.29 15.56 NA 9.05
12. S334E:T340E* fn 17.76 NA 9.26 17.07 NA 17.12
13. S338E:T340E* in NA 14.3 16.29 NA 6.2 9.0
13. S338E:T340E* fn NA 14.2 19.09 NA 10.6 15.1
14. S334E* in 14.3 NA NA 15.6 NA NA
14. S334E* fn 17.4 NA NA 16.9 NA NA
15. T340E* in NA NA 16.3 NA NA 9.0
15. T340E* fn NA NA 15.3 NA NA 15.4
Key: in, initial state; fn, ﬁnal state.
*Parallel orientation (Fig. 2).
yPerpendicular orientation (Fig. 3).
zParallel orientation, different initial conformation of the rhodopsin tail analogue (Fig. 5).
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analog has refolded in the complex (Ca RMS is 5.58 A˚) as in
the case of the all-aspartic acid tail analog. However, in this
particular case, we ﬁnd that residue E338 on the rhodopsin tail
analog will interact with the K14 residue on R-arrestin (Fig.
6). This interaction was not seen in the all-aspartic acid
analog. Moreover, the all-glutamic acid analog did not show
any evidence of a E334-K14 interaction or E340-K15 inter-
action, as in the all-aspartic acid case. We also created a two
additional mutants in a parallel orientation: S334E:T340E
and S338E:T340E. Although we know from experimental
evidence that the S334E:T340E mutant should interact with the
R-arrestin (as well as the S334D:T340D mutant), we could ﬁnd
no evidence of this interaction for the glutamic acid
analogue. The bulky side chains of the glutamic acid mutant
proved to be difﬁcult to simulate. Thus we preformed only
one simulation for each glutamic acid mutant. Based on our
limited simulations, we ﬁnd a somewhat weaker interaction
between the glutamic acid tail analog and the R-arrestin
protein, compared to the aspartic acid analog.
EXPERIMENTAL IN VITRO RESULTS
Given the results of the computational study, we generated
rhodopsin mutants with aspartic acid residues substitutions at
speciﬁc sites on the cytoplasmic tail. We constructed eight
mutant rhodopsin proteins and studied the effect of arrestin-
mediated deactivation. The results are presented in Fig. 7.
Most strikingly we ﬁnd that the double mutant with aspartic
acid substituted at positions 334 and 340 (D334/D340) shows
an arrestin effect that is comparable with all phosphorylat-
able residues replaced with aspartate (D-tail). This result
conﬁrms that the presence of a negative charge at these
speciﬁc positions is sufﬁcient to induce an arrestin effect.
However, it is also clear from Fig. 7 that the aspartic D-tail
mutant does not produce as strong an effect as phosphor-
ylation of the cytoplasmic tail. It is also evident that a single
negative charge present at either position 334 or 340 is not
sufﬁcient, although a negative charge at residue 334 does
increase the arrestin effect relative to the unphosphorylated
wild-type rhodopsin. To test whether the interactions seen
were indeed site-speciﬁc, we mutated residues 335 and 343
to aspartic acid and subsequently tested the construct using
our in vitro assay. We ﬁnd that this mutant showed no
interaction with the arrestin protein, as predicted from the
computer simulations. Taken all together, these results sug-
gest that the computer simulations can guide speciﬁc in vitro
experiments in this system.
FIGURE 3 The initial structure of the cytoplasmic tail of rhodopsin
(perpendicular orientation) in association with R-arrestin.
TABLE 3 Monte Carlo simulated annealing of C-tail rhodopsin/
arrestin: residue-residue interaction distances in A˚
Simulation Structure S343-K14 S343-K15
2. All-D mutant* in 19.14 15.78
2. All-D mutant* fn 23.89 22.04
4. All-D mutanty in 12.6 8.33
4. All-D mutanty fn 11.46 8.55
11. All-E mutant* in 21.39 17.22
11. All-E mutant* fn 15.76 7.35
Key: in, initial state; fn, ﬁnal state.
*Parallel orientation (Fig. 2).
yParallel orientation, different initial conformation of the rhodopsin tail
analogue (Fig. 5).
FIGURE 4 The ﬁnal structure of the all-aspartic acid mutant of the
C-terminus tail of rod-speciﬁc visual pigment rhodopsin (blue) in com-
plex with rod-speciﬁc arrestin protein (red). The charge-charge inter-
actions between the Asp334/Lys15 and Asp340/His301 are shown in stick
representation. The ﬁnal structure was found by a Monte Carlo simulated
annealing algorithm and this ﬁgure was generated using RASMOL (Sayle
and Milner-White, 1995).
FIGURE 5 The initial structure of the cytoplasmic tail of rhodopsin
(parallel orientation, Table 2z) in association with R-arrestin.
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CONCLUSIONS
In total 17 simulationswere performed, including a simulation
to predict a putative structure for the cytoplasmic tail of
rhodopsin. We ﬁnd that the peptide analog of the rhodopsin
cytoplasmic tail begins with an a-helix until residue V337,
and thereafter the tail adopts a more random loop structure.
This result is somewhat consistent with recent EPR spectro-
scopy that indicates the cytoplasmic tail is part of a short
H-VII helix (residues 328–333; Altenback et al., 2001); how-
ever, solution NMR studies indicate that the tail is dyna-
mically disordered beyond residue 327 (Langen et al., 1999).
Tables 1–3 summarize the conformational energetics, Ca
root mean-square deviation (RMSD) (Table 1) and the
residue-residue interaction distance (Table 2) between the
initial and ﬁnal structures of various mutated rhodopsin-
arrestin complexes which we have simulated. We note that
the alanine mutant is not represented in Tables 1 and 2,
inasmuch as it is similar to the wild-type simulation. We ﬁnd
that both the glutamic acid and aspartic acid mutated tail
analogs produced a slight conformational change in
R-arrestin (0.56 and 0.133 A˚). However, both of the nega-
tively charged tail mutants refolded into completely new
conformations when introduced in complex with R-arrestin
(5.58 and 5.269 A˚). Moreover, both the aspartic and glutamic
acid tail analogs showed potential charge-charge interactions
with R-arrestin, although at different sites. For example, in
the aspartic tail analog we see speciﬁc interactions of S334D
(tail) with K15, K300, H301, and R29 (R-arrestin) and also
T340D (tail) with K15 (R-arrestin) (Fig. 4), whereas the
glutamic tail analog mainly interacts at S338E (tail) with K14
(R-arrestin) (Fig. 6).
What about the role of the serine 343 residue in the
rhodopsin cytoplasmic tail? There is compelling in vivo and
in vitro work to suggest that this serine residue is indeed
phosphorylated, and as such, the question is, does it play
a role in desensitization (Ohguro et al., 1995, 1996; Zhang
et al., 1997; Kennedy et al., 2001b). To address this issue, we
have analyzed our simulation results for the interaction of
residue 343 with the arrestin lysine residues (K14, K15) of
interest (Table 3). We ﬁnd, in one simulation (the all-
glutamic acid mutant, conformation 1), an interaction
between E343 (rhodopsin) and K15 (arrestin). Moreover, this
is an obvious interaction as the interaction distance changes
from 17.22 A˚ to 7.35 A˚. The question is how to interpret
these results, since we ﬁnd only one simulation with an
obvious rhodopsin S343 interaction with arrestin. In all other
simulations studied, we consistently see interactions of
rhodopsin residues S338, T340, and strikingly S334 with the
arrestin protein. One possibility could be that we have simply
not run enough simulations to sample all possible inter-
actions of rhodopsin with arrestin. We are currently running
multiple mutant glutamic acid simulations to test this
hypothesis.
Another possibility is, if phosphorylated, residue S343 will
have a weak, but viable interaction with the arrestin protein.
We tested this hypothesis with our in vitro assay (Fig. 7). We
ﬁnd that single mutants of aspartic acid on any phosphor-
ylated rhodopsin residue produces a relatively insigniﬁcant
arrestin effect, with the possible exception of residue D334.
Moreover, the double mutant D335/D343 also produces an
insigniﬁcant arrestin effect. This suggest that the role of
residue S343 in desensitization is secondary at best. However,
a polar (negative) charge at this position may facilitate the
formation/stabilization of the rhodopsin-arrestin complex.
FIGURE 7 This ﬁgure illustrates the effect of arrestin binding with
various aspartic acid (D) rhodopsin mutants. Arrestin blocks transducin
binding and this is measured as an arrestin effect. The largest effect is seen
for the D334/D340 mutant, second column. The experiments were performed
after the simulations and were design based on our computational results.
The error bars are mean 6 SE.
FIGURE 6 The ﬁnal structure of the all-glutamic acid mutant of the
C-terminus tail of rod-speciﬁc visual pigment rhodopsin (blue) in com-
plex with rod-speciﬁc arrestin protein (red). The charge-charge interac-
tions between the Glu338/Lys14 are shown in stick representation. The
ﬁnal structure was found by a Monte Carlo simulated annealing algorithm
and this ﬁgure was generated using RASMOL.
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We stress that we have not tested all possible mutant
combinations involving residue S343; we merely suggest
that, if one relates the distance between the ion pair residues
to the strength of this interaction, that the order of afﬁnity
would be S334[T340[S338[S343. This would imply that
mutation of the S334 residue could have a signiﬁcant effect
on the binding of the rhodopsin-arrestin complex. Our re-
sults are consistent with the dephosphorylation results of
Palczewski and co-workers, who ﬁnd that dephosphorylation
occurs in the following order (slowest to fastest): S334\S338
\ S343 (Ohguro et al., 1996).
We believe that our ﬁndings may be signiﬁcant, inasmuch
as it is thought that the rhodopsin residues Ser334, Ser338, and
Thr340 are key phosphorylation sites (McDowell et al.,
2001). Our results also indicate the relative importance of the
R-arrestin Lys14 and Lys15 as a possible charge-charge
interaction site (Vishnivetskiy et al., 2000). Moreover, we
ﬁnd that the orientation of the cytoplasmic tail of rhodopsin
in the binding pocket of arrestin is important. That is to say,
only a parallel tail orientation facilitates binding, whereas
a perpendicular orientation did not seem to show any in-
teraction between the two proteins. We also note that our
simulations do not show any evidence of a signiﬁcant role of
the other serine/threonine residues in this binding process.
We must stress that this is the ﬁrst computational study of
such a system.
Based on our computational studies, we predicted that the
S334D/T340D aspartic acid mutant analog of rhodopsin would
bind to arrestin in a comparable way to phosphorylated
rhodopsin. This hypothesis was tested with our in vitro
assays (Fig. 7) and results indicate this to be the case. We are
now in the process of studying the effect of this ionic in-
teraction, both experimentally and computationally.
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